Last updated on March 2018

A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors

Brief description of study

This phase III, double blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission in participants with moderately to severely active ulcerative colitis (UC) who are refractory to or intolerant of TNF inhibitors.

Clinical Study Identifier: NCT02100696

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GA28950 ...

AZ Sint Elisabeth Herentals
Herentals, Belgium
  Connect »